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Conditional expression of diphtheria toxin receptor (DTR) is widely used for tissue-specific
ablation of cells. However, diphtheria toxin (DT) crosses the blood–brain barrier, which limits
its utility for ablating peripheral cells using Cre drivers that are also expressed in the central
nervous system (CNS). Here we report the development of a brain-sparing DT, termed
BRAINSPAReDT, for tissue-specific genetic ablation of cells outside the CNS. We prevent
blood–brain barrier passage of DT through PEGylation, which polarizes the molecule and
increases its size. We validate BRAINSPAReDT with regional genetic sympathectomy:
BRAINSPAReDT ablates peripheral but not central catecholaminergic neurons, thus avoiding
the Parkinson-like phenotype associated with full dopaminergic depletion. Regional sym-
pathectomy compromises adipose tissue thermogenesis, and renders mice susceptible to
obesity. We provide a proof of principle that BRAINSPAReDT can be used for Cre/DTR tissue-
specific ablation outside the brain using CNS drivers, while consolidating the link between
adiposity and the sympathetic nervous system.
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C
onditional expression of the diphtheria toxin receptor
(DTR) using the Cre/lox system is a widely used tool for
tissue-specific ablation of cells. However, this tool is of
limited utility for targeted genetic ablation of peripheral cells
because diphtheria toxin (DT) crosses the blood–brain barrier
(BBB) and many peripheral Cre drivers have additional
expression in the central nervous system (CNS), thus driving
ablation in the brain.
The ability of a molecule to cross the BBB depends on two
critical molecular properties: polarity and size. Small uncharged
molecules tend to cross the BBB, whereas those that are large
and/or polarized tend to have limited permeability. To limit DT
action and prevent it from entering the brain, we chemically
modified DT by PEGylation to develop a brain-sparing DT
(BRAINSPAReDT). This chemical modification increases the size
and polarity of DT and spares DTR-expressing cells in the brain.
To validate this tool in vivo, we implemented a genetic method
for regional sympathectomy using BRAINSPAReDT.
General sympathectomy has been traditionally performed
with systemic injection of chemicals such as guanethidine or
6-hydroxydopamine1. Unlike the chemical ablation, which is
systemic, surgical sympathectomy is a localized intervention that
affects the sympathetic nervous system (SNS) innervation of a
confined anatomical region or organ2–4. However, surgical
sympathectomy damages nerves of unknown identity that are
mixed within the SNS bundles5. Moreover, neither a surgical nor
a chemical approach is amenable to specifically sympathectomize
organs such as the adipose tissue, which covers a large body
region.
Thus, genetic ablation via expression of Cre-inducible DTR
and diphtheria toxin injection would be a feasible strategy to
achieve a regional sympathectomy and tissue specificity6. Using a
catecholaminergic Cre driver (TH-Cre), we conditionally express
the DTR in the SNS and dopaminergic neurons in the brain. In
these mice, BRAINSPAReDT successfully ablates peripheral
catecholaminergic neurons, but not dopaminergic neurons in
the brain, and thus avoids the Parkinson-like phenotype that is a
consequence of dopaminergic depletion. We found that
PEGylated DT (PEGyDT)-regionally sympathectomized mice
have defective thermogenesis, which is a key mechanism of
energy dissipation from brown and beige adipose tissues. Thus,
mice regionally sympathectomized with BRAINSPAReDT are
prone to obesity, despite having normal eating behaviour. These
results are consistent with the role of the SNS in lipolysis and
thermogenesis. We provide a proof-of-principle demonstration
that BRAINSPAReDT can generally be used for Cre/DTR
ablation in the periphery, thus circumventing off-target cell
ablation in the brain. In particular, BRAINSPAReDT may now be
used for genetic loss of function of subsets of SNS neurons. This
tool should enable systematic molecular study of the SNS as well
as a plethora of peripheral neurons or cells that may be labelled
by CNS markers.
Results
Increased hydrodynamic radius and polarity of PEGylated DT.
The covalent attachment of long unstructured polyethylene glycol
(PEG) chains—PEGylation—to proteins results in increased
hydrodynamic radius, or size, of the biomacromolecule, as well as
increased polarity7–10. In the case of DT, lysines were used as
conjugation sites (Fig. 1a). The use of an N-hydroxysuccinimidyl
(NHS) ester PEG derivative, NHS-PEG4, enables a fast reaction
with the most accessible and reactive e-amine side chains of lysine
on the surface of DT (Fig. 1b).
The modification state of DT was analysed by mass spectro-
metry to estimate how many PEG molecules were attached to DT
(Fig. 1c; Supplementary Fig. 1). DT (G2–S536) has a molecular
weight of 58,336Da, and matrix-assisted laser desorption/
ionization–time-of-flight (MALDI–TOF) analysis showed the
best-resolved signal as [Mþ 2H]2þ peak at 29,169m/z. PEGyDT
showed additional peaks at m/z values 29,274, 29,381, 29,484,
29,591 and 29,702 that correspond, respectively, to masses (Da) of
58,547, 58,761, 58,967, 59,181 and 59,403 (Fig. 1c). Within a
margin of variation, these values are in agreement with the
expected mass additions (218Da) for PEGylation. Conversion of
DT to PEGyDT was nearly complete (relative 95% conversion)
and resulted in a heterogeneous mixture differing in both the
copy number of PEG units and conjugation sites. On the basis of
our MALDI–TOF data, each DT molecule was modified with one
to five PEG units, representing an average increase of molecular
weight of 436Da.
PEGylated DT remains fully functional after modification. To
assess the efficiency of PEGyDT in promoting cell death, fluor-
escence-activated cell sorting (FACS) analysis was performed
using HeLa cell cultures that were pre-incubated with vehicle, DT
or PEGyDT (Fig. 1d,e; Supplementary Fig. 2a,b). HeLa cells are
human, and thus express DTR, which has been cloned into mice
to generate the Rosa26-LSL-DTR mouse line6. As shown in
Fig. 1e, in vehicle-treated cultures, after 24 h, background cell
death amounted to 9.70±0.39% (cell death was assessed by
propidium iodide uptake). After 24 h of incubation with toxin,
DT and PEGyDT (6.50 nM), the cell death was increased to
57.23±0.63% and 52.57±0.04% (***Po0.0001, one-way analysis
of variance (ANOVA), followed by Tukey test), respectively. After
48 h, the cell death was 98.57±0.10% for DT and 98.60±0.05%
for PEGyDT, but only 7.45±0.12% for vehicle-treated cells
(***Po0.0001, one-way ANOVA, followed by Tukey test).
Hence, PEGyDT does not have any impairment in its cytotoxic
activity towards DTR-expressing cells.
BRAINSPAReDT ablates peripheral but not central neurons.
To test the tissue-specific ablation efficiency of PEGyDT in
rodents, we performed histological and behavioural analysis with
a catecholaminergic Cre driver line, which targets the locus of the
gene encoding for tyrosine hydroxylase (TH), a major enzyme
in the biosynthetic pathway of catecholamines, such as nore-
pinephrine (NE) and dopamine11. The TH-Cre driver line was
crossed to the Rosa26-LSL-DTR mouse line (TH-Cre; LSL-DTR),
and these mice were injected intraperitoneally (i.p.) with saline,
DT or PEGyDT (0.02 pmol g 1 of body weight (BW))6. At 24 h
following injections, mice were killed to analyse the presence of
the catecholaminergic marker, TH, in brain (Fig. 2a) and in nerve
fibres (Fig. 2b) from subcutaneous (SubQ) white adipose tissue
(WAT). As shown in Fig. 2c, the THþ /4,6-diamidino-2-
phenylindole (DAPI) ratio in the ventral tegmental area of the
brain of mice that received DT was 4.00±1.38% (***Po0.0001,
one-way ANOVA, followed by Tukey test), while that of
PEGyDT-injected mice was 51.00±7.17% (***Po0.0001,
one-way ANOVA, followed by Tukey test). Vehicle-injected
mice had a THþ /DAPI ratio in the brain of 50.18±10.22%. The
same analysis was performed in other brain areas containing
THþ neurons (Supplementary Fig. 3 for area postrema,
locus coeruleus, hypothalamus and sagittal plane of substantia
nigra), and the results indicate that PEGyDT does not
ablate catecholaminergic neurons in the brain when injected
systemically. We probed the efficiency of PEGyDT for tissue-
specific ablation of sympathetic neurons in the same mice. To this
end, we dissected nerve fibres in fat pads of the aforementioned
TH-Cre; LSL-DTR mice for immunostaining against TH and
b3-Tubulin (b3-Tub), a general marker of peripheral nerves
(Fig. 2b). DT-injected mice had a THþ /b3-Tub ratio of
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11.08±1.78%, and PEGyDT-injected mice had a ratio of
11.80±1.17%. These values are significantly lower than that
of vehicle-injected mice in which the ratio is 102.77±9.48%
(***Po0.0001, one-way ANOVA, followed by Tukey test), as
shown in Fig. 2d. Furthermore, we confirmed that levels of TH
transcripts in SNS ganglia (superior cervical ganglia) of regionally
sympathectomized mice are significantly lower than that of
PEGyDT-injected LSL-DTR mice (Supplementary Fig. 4a).
We also verified that the DT-injected mice, but not those
injected with PEGyDT, had decaying health that was accom-
panied by severe Parkinson-like movement, weight loss and
reduction in food intake that leads to premature death (Fig. 3).
A blind scoring test was performed to evaluate Parkinson-like
movements, which are characterized by the presence of jerks and
shakes when mice initiate movement (Supplementary Movies 1
and 2). PEGyDT-injected TH-Cre; LSL-DTR mice moved
normally, whereas DT-injected mice had marked alterations in
locomotor behaviour that mimic a Parkinson-like phenotype
(Fig. 3b; Supplementary Movies 1 and 2). DT-injected TH-Cre;
LSL-DTR mice had decaying health that was evidenced by
severely reduced food intake and weight loss (Fig. 3c,e). In 1
week, the BW of DT-injected TH-Cre; LSL-DTR mice was
reduced by 15% (Fig. 3c, *Po0.01, unpaired t-test) and the food
intake was reduced from 3 g per day to only 1 g per day (Fig. 3e,
**Po0.001, unpaired t-test). These decreases were not observed
following injection with PEGyDT. Weight curves and food intake
of PEGyDT-injected TH-Cre; LSL-DTR mice were similar to that
of the control line LSL-DTR (Fig. 3d,f). The decaying health of the
Parkinson-like mice required euthanasia to comply with humane
criteria for animal handling. Altogether, these results indicate that
PEGyDT ablates cells peripherally, but not those in the brain.
Regional sympathectomy impairs thermogenesis and NE. To
probe a physiological effect of PEGyDT regional sympathectomy,
we measured its impact on the defence of body temperature. At
room temperature (RT, 25 C), regionally sympathectomized
mice had a slightly lower body temperature (36.0±0.2 C) that
was not significantly different from that of PEGyDT-injected
LSL-DTR mice, which are hereafter referred to as controls
(36.4±0.2 C, Fig. 4a, t¼ 0 h, NS, P¼ 0.254, n¼ 5). As RT is only
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Figure 1 | PEGylation of DT and its in vitro functionality after modification. (a) PEG residues bind to the lysines in DT. (b) Schematic representation
of PEGylation of DT through conjugation of NHS-PEG4 at lysines. (c) Mass spectrometry of DT (left) and PEGyDT (right) samples. DT peak is identified in
red and PEGyDT peaks are identified in green. (d) Live- and dead-cell populations after 48 h of incubation with vehicle, DT and PEGyDT in HeLa cells.
(e) Time course of cell death after incubation with vehicle, DT and PEGyDT (***Po0.0001, n¼ 3). Statistics were performed using one-way ANOVA test
followed by Tukey test. Data are represented as mean±s.e.m. (related to Supplementary Figs 1 and 2).
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a few degrees below the murine thermoneutral temperature
(30 C), we challenged mice with cold (4 C), to test the effect of
regional sympathectomy on adaptive thermogenesis, which is
thought to be mediated by the SNS. Control and regionally
sympathectomized mice were exposed to 4 C for 8 h, and their
body temperature was measured after the challenge (Fig. 4a,
t¼ 8 h). While control mice had only a 2 C reduction in body
temperature, regionally sympathectomized mice doubled that
decrease, dropping to a body temperature of 32.1±0.4 C
(Fig. 4a, t¼ 8 h, ***Po0.0001, unpaired t-test). Shivering
thermogenesis does seem to be majorly affected (Supplementary
Movies 3 and 4). The defence of BW in response to a cold shock
is typically accompanied by SNS release of NE in the brown
adipose tissue (BAT). This also occurs in the SubQ WAT where
a consequent increase in thermogenic gene expression in this
tissue has been referred to as ‘browning’ or ‘beiging’. However,
this typical response was not seen in mice regionally sym-
pathectomized with BRAINSPAReDT, which had significantly
lower levels of NE in SubQ fat and in BAT, but not in other
organs (Fig. 4b; Supplementary Fig. 4b). To explain the lack
of decreased NE in some peripheral organs, we characterized
TH-Cre by immunofluorescence on mice crossed with a
reporter LSL-ChR2-YFP reporter. We discovered incomplete
co-localization of TH and ChR2-YFP reporter in the thoracic
ganglia of the sympathetic chain. We see that only 59.62±4.22% of
THþ neurons are YFPþ and this explains the lack of decreased
NE in the organs innervated by these ganglia. However, the 13th
ganglia of the sympathetic chain, which is known to innervate the
adipose tissue12, shows a co-localization of THþ neurons and
GFPL10þ of 94.25±10.41% (Supplementary Fig. 4c). This
complete overlap in fat is consistent with the marked decrease in
NE content that we measure in fat (Fig. 4b; Supplementary Fig. 4b).
Thus, we can conclude that, outside the brain, the TH-Cre driver
line is a peripheral mosaic that preferentially marks neurons
innervating fat, but not vital organs such as heart and lungs. The
mosaicism of this TH-Cre driver mouse line may be due to
insertional effects of the transgene, which alter the activity of the
promoter in a tissue-specific manner.
Consistent with a lower NE tone in fat, we observed
significantly lower levels of thermogenic gene expression in SubQ
fat (Fig. 4c). These results confirm that genetic regional
sympathectomy with BRAINSPAReDT has a physiological effect
on adaptive thermogenesis.
To further understand the mechanism behind our data, we
performed a leptin challenge (Fig. 4d). As expected the food
intake was reduced to roughly 1 g per day both for controls and
regionally sympathectomized mice. Nevertheless, the effects of
leptin on weight loss were lower in regionally sympathectomized
mice, further confirming that an intact sympathetic innervation
on fat is required for leptin’s effect on BW5.
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Regional sympathectomy predisposes obesity. For more com-
plete metabolic phenotyping, regionally sympathectomized mice
were challenged with high-fat diet (HFD). On a HFD, mice that
were regionally sympathectomized with BRAINSPAReDT gain
more weight compared to controls (Fig. 5a,b, **Po0.001,
***Po0.0001, unpaired t-test) compared to controls: TH-Cre;
LSL-DTR mice weight was 39.43±1.83 g after 4 weeks on HFD,
while control LSL-DTR mice weight was only 25.23±1.42 g after
the same time (the schematic timeline of injections and HFD is
shown in Supplementary Fig. 5a)13. The increase in BW was due
to a significant increase in fat mass (63% increase), which was
accompanied by a decrease in lean mass (13% decrease, Fig. 5c).
The speed of weight gain was also significantly higher for TH-Cre;
LSL-DTR mice than for control LSL-DTR mice (**Po0.001,
unpaired t-test). While control mice gained 9.23±0.72 g per
month, TH-Cre; LSL-DTR mice gained nearly threefold
(22.18±1.06 g per month) in BW (Supplementary Fig. 5b). As
the BRAINSPAReDT ablation is temporally controlled to take
place in adulthood, no changes in body length were observed
(Supplementary Fig. 5c).
Notably, mice sympathectomized with BRAINSPAReDT
remained obese after withdrawal of HFD (Fig. 5d,
***Po0.0001, unpaired t-test). After 40 days of HFD withdrawal,
regionally sympathectomized mice weighed 38.20±2.87 g, which
was 35.46% higher than the initial weight before HFD. However,
control mice reverted back to baseline, weighting only 2% more
than the initial weight before HFD (Fig. 5d). We questioned
whether the sustained elevation in BW was caused by alterations
in food intake. We verified that this is not the case, as food intake
isB3 g per day for both experimental and control mice (Fig. 5e).
Thus, the ratio of BW and food intake translated into higher feed
efficiency in regionally sympathectomized mice, relative to
control mice (Supplementary Fig. 5d).
Moreover, mice sympathectomized with BRAINSPAReDT
displayed glucose intolerance, when on a normal diet (ND)
regimen, contrasting with the normal glucose tolerance test of
LSL-DTR control mice, which were also injected with PEGyDT
(Fig. 5f, **Po0.001, unpaired t-test).
The previous sympathectomy drugs, such as
6-hydroxydopamine neurotoxin, were known to increase
catecholamines production, which normalizes after 2 weeks14.
Thus, we also controlled for this temporal window, and
challenged PEGyDT-ablated mice with HFD only 2 weeks after
regional SNS ablation, to allow for normalization of hypothetical
elevation of catecholamine levels. We verify that differences in
BW were the same when mice were fed with HFD right after the
ablation procedure or only 2 weeks after regional SNS ablation
(Supplementary Fig. 5e **Po0.001, unpaired t-test).
Obesity is coupled to low thermogenesis and hypoactivity.
Similar to what was done for the cold challenge, we measured NE
content and thermogenic gene expression in the adipose tissue of
mice fed an obesogenic diet. Mice that were sympathectomized
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with BRAINSPAReDT had an NE content (pg mg 1 of protein)
in SubQ WAT that was significantly lower than that of
controls (38.71% decrease, ****Po0.00001, unpaired t-test,
Supplementary Fig. 4b). Moreover, and consistent with a lower
NE tone in fat, we observed lower levels of thermogenic gene
expression not only in this tissue but also in BAT (Fig. 6a,b;
Supplementary Fig. 6a). In addition, UCP1 levels are also
decreased in BAT of mice sympathectomized with BRAIN-
SPAReDT (Supplementary Fig. 6b). Notably, total protein
content was increased in BAT (as well as in SubQ WAT and
visceral WAT; Supplementary Fig. 7a–c), indicating that the total
UCP1 content in the tissue, which is the most relevant parameter
for non-shivering thermogenic capacity15,16, is even more
decreased in regionally sympathectomized mice (UCP1/protein
BAT (a.u.) is 6.0±0.36 for controls and 4.9±0.24 for regionally
sympathectomized; *Po0.01 and **Po0.001, unpaired t-test).
Finally, and for more complete metabolic phenotyping, we kept
obese mice and controls in metabolic cages for 3 days (after
4 weeks on HFD). On HFD, mice that were sympathectomized
with BRAINSPAReDT had lower levels of nocturnal locomotion
compared to controls (Fig. 6c; Supplementary Fig. 7d–f).
However, the energy expenditure and the respiratory quotient
remained normal in mice that were sympathectomized with
BRAINSPAReDT (Fig. 6c; Supplementary Fig. 7d–f).
Discussion
The conditional Cre; LSL-DTR system is widely used for tissue-
specific loss of function and genetic ablation of cell lineages6.
The use of this system is contingent on a tightly regulated tissue-
specific expression of Cre driver lines. Brain expression of
peripheral Cre drivers may reflect not only insertion artefacts that
dysregulate the transgene, but may also reflect cell lineage or
biological function when the same gene is expressed in peripheral
and central populations of cells.
Brain expression in many peripheral Cre drivers is a recurrent
problem that has been limiting the use of the Cre; LSL-DTR
system for ablating peripheral tissues, due to off-target effects. For
instance, TH is an enzyme in the biosynthetic pathway of
catecholamines, which include dopamine and NE. TH has been
used as a marker and molecular handle to genetically manipulate
catecholaminergic neurons with optogenetic techniques, which
have a localized action5,17–19. The TH-Cre driver line labels
dopaminergic neurons in the brain, as well as sympathetic
neurons. As such, whole-body applications that require the
systemic delivery of a toxin, like in the Cre; LSL-DTR system,
have limited power because DT crosses the BBB.
To address this general problem, we developed a chemical
genetic approach, named BRAINSPAReDT, in which we
chemically modified DT by PEGylation (PEGyDT), so that it
spares an action in DTR-expressing cells in the brain.
PEG is a non-toxic, non-immunogenic and non-antigenic
biocompatible polymer that has been used as an excipient
in many pharmaceutical and cosmetic formulations8,9,20.
PEGylation increases hydrodynamic radius, polarity and
molecular weight21.
Permeability across the BBB is contingent on polarity and
molecular weight, favouring non-polar and smaller molecular
weight molecules22. Increased molecular weight and polarity is a
known problem for CNS drug delivery, but a unique advantage
for keeping DT away from the brain23. Thus, as shown here,
increasing the polarity and the molecular weight of DT by
PEGylation is a feasible way to prevent DT’s action in the brain.
PEGyDT had an average increase in molecular weight by
436Da, but it was just as efficient as DT in mediating tissue-
specific cell death, both in vitro and in vivo. The latter was herein
validated by analysing a Cre driver line, labelling populations of
neuronal cells in the brain and in the periphery. We verified that
genetic ablation of catecholaminergic neurons in the CNS led to a
Parkinson-like phenotype, which is a major impairment for
analysing the effect of regional SNS loss of function in a
metabolic/obesity context. Parkinson-like mice have deteriorating
health that leads to an emaciated state, which could be confused
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Figure 6 | Obese mice sympathectomized with BRAINSPAReDT have deficits in thermogenic gene expression and nocturnal hypoactivity but normal
energy expenditure. (a) Thermogenic gene expression in SubQ adipose tissue (*Po0.01, **Po0.001, ***Po0.0001, n¼ 6). (b) Thermogenic gene
expression in BAT (*Po0.01, n¼ 7 for Symp and n¼ 8 for Control). The a.u. used in a,b is the same. The data were normalized to GAPDH and SYBR
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unpaired t-test. Data are represented as mean±s.e.m. (related to Supplementary Figs 6 and 7). EE, energy expenditure; NS, not significant; RQ, respiratory
quotient.
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with healthy weight loss. Alternatively, PEGyDT-mediated
genetic regional ablation of the SNS spared catecholaminergic
neurons in the CNS, and created a suitable rodent model system
with which to study SNS function.
Our previous studies only probed the local role of SNS fat
innervation in mediating lipolysis locally, in a single fat pad5.
Here we probed whether this effect generalizes to systemic levels
such as to control whole-body adiposity and metabolism.
To achieve this, we performed a regional genetic loss of
function of the SNS, that is, a regional genetic sympathectomy.
Sympathectomy procedures that have been used in the
past included chemical ablation with guanethidine or
6-hydroxydopamine24–27. Despite the experimental differences,
we are able to draw parallels between classical studies and our
findings, as follows: if not challenged by a HFD or cold, mice
treated with BRAINSPAReDT present normal BW, and other
metabolic parameters, which is consistent with results reported
in classical studies involving chemical sympathectomy24,25. When
challenged with a HFD, we then see an effect in obesity and
thermogenesis that is similar to results previously reported27.
However, it was also reported that mice chemically
sympathectomized with guanethidine do not become obese
after a human supermarket diet26. Of note, another study
disclosed that guanethidine treatment lead to pruritus, open
sores and skin necrosis25. We also observed that chemical
sympathectomy caused malaise (data not shown). Finally,
chemical ablation with 6-hydroxydopamine is classically used as
a parkinsonian agent, and thus ablates beyond the SNS, affecting
dopaminergic neurons in the brain28. BRAINSPAReDT does not
cause any malaise or side effects, due to its tissue specificity and
deficient access to the brain.
Studies using surgical techniques (ganglia removal or axotomy)
reported findings similar to ours in several species (rats, rabbits,
cats and hamsters). Several of these studies report localized fat
accumulation and impaired fat mobilization2–4.
Taking the classical literature and our results into account,
genetic ablation via BRAINSPAReDT, with expression of
Cre-inducible DTR and PEGyDT injection, is an amenable way
to combine tissue specificity for the SNS, and a regional action
enabled by the Cre driver line. We used a sympathetic Cre driver
that has a mosaic pattern of expression, which preferentially
marks SNS neurons innervating fat and avoids other organs such
as heart and lungs. The mosaicism of this TH-Cre driver mouse
line may be due to insertional effects of the transgene, which alter
the activity of the promoter in a tissue-specific manner.
This restricted Cre expression within the SNS enabled
regional sympathectomy with BRAINSPAReDT, rendering mice
extremely vulnerable to metabolic challenge, while compromising
several key elements in mechanism for energy dissipation.
Consistent with the known role of NE in driving thermogenesis,
mice sympathectomized with BRAINSPAReDT have deficient
adaptive thermogenesis, which is accompanied by a down-
regulation of thermogenic genes and NE content in adipose
tissues. In addition, sympathectomy with BRAINSPAReDT
rendered mice extremely prone to metabolic syndrome and
obesity, as seen during a HFD challenge.
Mice regionally sympathectomized were glucose intolerant and
did not normalize excess weight upon HFD withdrawal, as it
would be expected. Instead, increased weight plateaued upon
HFD withdrawal. Whereas we cannot exclude a role of the
adrenals in the phenotype we see, leptin action does not depend
on intact adrenal glands29. Thus, the persistence of adiposity in
regionally sympathectomized mice, as well as the defective
responses to leptin, is consistent with the known role of
sympathetic neuro-adipose junctions in driving lipolysis and fat
mass reduction5. The lack of WAT mobilization in regionally
sympathectomized mice is consistent with the lack of adaptive
thermogenesis. Finally, under HFD, regionally sympathectomized
mice have reduced nocturnal activity, which further reduces
energy dissipation. As a consequence of regional SNS loss of
function, mice appeared to have sustained obesity, even though
eating behaviour was normal.
Future studies will attempt to develop versions of DT that can
ablate the innervation to specific organs or specific peripheral
tissues/cell types. This may be achieved by using Cre driver mice,
where the expression is restricted to neurons innervating specific
organs.
While consolidating the appetite-independent link between
adiposity and the SNS, our results provide a proof of principle
that BRAINSPAReDT can generally be used for Cre/DTR tissue-
specific ablation outside the brain using CNS Cre drivers. For
instance, several subpopulations of immune cells express
neurotransmitter or CNS receptors. However, the functional role
of such neuro-like immune cells remains elusive30,31. In this
regard, BRAINSPAReDT can now be used for loss-of-function
studies using CNS Cre drivers. Overall, BRAINSPAReDT
will promote the advancement of emerging fields of research
such as neuroimmunology, which lay at the interface between
neurobiology and physiology.
Methods
PEGylation reaction. An amount of 1mg of DT Corynebacterium diphtheriae
(Calbiochem) was reconstituted in 1ml of conjugation PBS 1x (concentration
17 mM). Modification was performed using 80 equiv. of modifying agent in relation
to DT. Hence, 0.001269mmol of crosslinker was needed. Mass spectrometry
(PEG)4 methyl-PEG-NHS-Ester (Life Technologies), after being fully equilibrated
to RT, was reconstituted in 1.1ml of dimethyl sulfoxide (Sigma-Aldrich), leading to
a concentration of 250mM PEG, according to the manufacturer’s instructions.
A concentration of 250mM PEG was diluted 1:100 in dimethyl sulfoxide and
then the appropriate volume was transferred into DT solution. The mixture was
incubated for 4 h, at RT, under shaking. To remove the excess of crosslinker,
gel filtration chromatography using the gravity protocol of PD MidiTrapG-25
column (GE Healthcare) was performed according to the manufacturer’s
indications. Briefly, the column was prepared and equilibrated with buffer. The
sample was applied to the column, the flow-through was discarded, and the eluate
was collected. The concentration of PEGyDT was determined using a NanoDrop
ND-2000 UV-Visible spectrophotometer (Fisher Scientific), measuring the
absorbance at 280 nm of 1 ml samples and using PBS buffer as blank.
Mass spectrometry. DT and PEGyDT samples were analysed by MALDI–TOF.
Samples were previously concentrated in Amicon Ultra-2, Ultracel-10 membranes
(Sigma-Aldrich) and prepared according to the manufacturer’s instructions
(centrifuged for 4min, 3,500g, with PBS 1x). DT and PEGyDT were centrifuged at
3,500g until appropriate concentration (10 mM).
Samples were desalted using a Millipore C4 Ziptip and eluted with 2 ml of
50% MeCN/0.1%TFA. A measure of 0.8 ml of this sample was mixed with 0.8 ml
20,50-dihydroxyacetophenone matrix (Fluka, 15mgml 1 in 75% EtOH containing
0.075M ammonium citrate) and 0.8 ml 2% trifluoroacetic acid. The sample was
air-dried onto a target plate and analysed in a Water MALDI microMX mass
spectrometer at threshold laser power in linear positive ionization mode.
Pulse–voltage settings were optimized for maximum resolution of the 2þ
charge-state peaks. External calibration was with a mixture of equine myoglobin
and bovine trypsinogen. Data were analysed using Waters Masslynx4.1 software.
Cell culture of HeLa cells. HeLa cells were obtained from the laboratory of Lars
Jansen at Instituto Gulbenkian de Cieˆncia (IGC) and maintained in Dulbecco’s
modified Eagle medium high glucose with L-glutamine and sodium pyruvate
(Biowest) supplemented with 10% fetal heat-inactivated (Biowest) and 1%
penicillin–streptomycin (Biowest)—Dulbecco’s modified Eagle medium complete
medium. Cells were maintained in humidified atmosphere, 5% CO2 at 37 C. Cells
were counted in a haemocytometer (Neubauer Cell with Double Grid, Fisher
Scientific) using 1% trypan blue solution (Sigma-Aldrich) and plated at 105 and
6 104 cells per well in 12- and 24-well plates (CORNING), respectively.
All incubations used a concentration of 6.50 nM of DT and PEGyDT. Different
time points (6–72 h) were prepared for FACS analysis. The medium and cells were
collected and cells were centrifuged for 4min, 3,250g, at 4 C. Cells were
resuspended in 150ml FACS buffer (2% FBS, 0.02% sodium azide-1-15N
(Sigma-Aldrich) in PBS 1x) and 25 ml propidium iodide (Sigma-Aldrich)
were added.
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Data were acquired in a Becton Dickinson Flow Cytometer FACSCalibur. Data
were acquired using CellQuest software (Becton Dickinson) and analysed in
FlowJo.
Mice and housing conditions. Mice (male and female) 12–16 weeks old were
housed at controlled temperature and humidity, under a 12 h light/dark cycle. Food
and water were supplied ad libitum, unless mentioned otherwise. The animal
experiments were performed in agreement with the International Law on Animal
Experimentation and were approved by the IGC ethics committee and by the USC
Ethical Committee (Project ID 15010/14/006). All controls were injected with
vehicle (PBS 1x). C57BL/6 mice were obtained from the Mice Production Facility at
IGC. TH-Cre (#008601), LSL-DTR (#007900), LSL-ChR2-YFP (#012569) and
GFPL10 (#024750) mice were purchased from Jackson Laboratory.
PEGyDT-mediated regional sympathectomy. TH-Cre; LSL-DTR mice were
used for this experiment and LSL-DTR mice were used as controls. During the
experiment, animals and food were weighed every day. Both DT and PEGyDT
were injected i.p. Injections of 0.02 pmol g 1 of BW of DT or PEGyDT were
administered once a day for 8 consecutive days.
Mice were perfused with PBS 1x followed by 4% formaldehyde (VWR). The
brain was removed and fixed in 4% formaldehyde for 2 days, at 4 C. Using a
vibratome VT 1000S (Leica), 50 mm-thick slices of ventral tegmental area, area
postrema, locus coeruleus, hypothalamus and substantia nigra were obtained.
These slices were at RT for 1 h, shaking in blocking buffer (1% bovine serum
albumin, 0.1% Tween 20 (Sigma-Aldrich), 0.05% sodium azide in PBS 1x). The
slices were incubated with the primary antibody TH chicken (1:1,000, Aves Lab,
#TYH) overnight shaking, at 4 C. After washing, secondary antibody Alexa Fluor
488 Goat Anti-chicken IgY (Hþ L; 1:500, Life Technologies, #A-11039) was
applied for 1 h, shaking, at RT. After secondary antibody incubation, slices were
washed and mounted with Dapi-Fluoromount-G (Southern Biotech). The slides
were dried at RT and then kept at 4 C.
Fibres isolated from inguinal fat were fixed in 2% formaldehyde for 2 h, at RT,
shaking. After blocking for 1 h, at RT, fibres were incubated with primary
antibodies rabbit polyclonal to neuron specific b3-Tub (1:1,000, Abcam, #ab18207)
and TH chicken, overnight, shaking, at 4 C. After washing, secondary antibodies
Alexa Fluor 488 Goat Anti-rabbit IgG (Hþ L; 1:500, Life Technologies, #A-11008)
and Alexa Fluor 594 Goat Anti-chicken were applied for 1 h, shaking, at RT. After
secondary antibodies incubation, fibres were washed and mounted with
Fluoromount-G. The slides were dried at RT and then kept at 4 C.
Confocal images were acquired with Leica TCS SP5 Inverted and Upright
Microscopes. Analysis and quantification of acquired images were performed
using FIJI.
Scoring test. After administration of 0.02 pmol g 1 of BW of DT or PEGyDT
once a day for 8 consecutive days, movies of mice were done. These movies were
presented to people blinded to the experiment, but experienced in working with
mouse models. The question ‘How many animals are moving normally?’ was asked.
Functional tests on regionally sympathectomized mice. Body rectal tempera-
ture was measured using an electronic thermometer (Precision) when the animals
were housed at RT and animals were weighed. After this, animals were housed at
4 C with ND food and water ad libitum. Body temperature was measured and
animals were weighed every hour for 8 h.
Mice were given 4 daily i.p. injections of either 2mg kg 1 leptin (Amylin
Pharmaceuticals Inc.) or PBS. BW and food intake were measured daily.
Animals were weighed and ND was replaced by HFD. Mice were weighed every
week for 4 weeks. HFD (Ssniff, Spezialdia¨ten GmbH, Soest, Germany) contains
60 kJ% fat. After 22 days, HFD was replaced by a ND regimen and, during this
period, mice were weighed and food intake was measured.
After 12 h fasting during the dark cycle, glucose was measured using Accu-Chek
Aviva Glucose (Roche Diagnostics). After this, an i.p. injection of 2mg g 1 D-(þ )-
glucose (Sigma-Aldrich) was administered and glucose level was measured at 15,
30, 60, 90 and 120min post injection. These procedures were performed on ND.
Nose-to-anal distance was measured.
ND was replaced by HFD 2 weeks after regional sympathectomy was performed
in TH-Cre; LSL-DTR mice and also in control LSL-DTR mice. Food intake and
weight were measured.
NE measurements (enzyme-linked immunosorbent assay). To assess the basal
content of NE in innervated organs, 12-week-old LSL-DTR and TH-Cre; LSL-DTR
mice were killed for tissue collection 1 week after 8 doses of PEGyDT (once a day).
To examine the effect of cold exposure (8 h) and of HFD (4 weeks) on the levels of
NE in WAT after regional sympathectomy, subcutaneous fat pads were collected
for homogenization right after the challenges. NE levels were determined with an
NE ELISA kit (Labor Diagnostika Nord GmbH). Tissues were homogenized and
sonicated in homogenization buffer (1N HCl, 1mM EDTA), and cellular debris
were pelleted by centrifugation at 16,000g for 15min at 4 C. All tissue samples
were normalized to total tissue protein concentration.
Quantitative PCR. Total RNA was isolated from either superior cervical ganglia or
SubQ fat pads using RNeasy Mini kit (Qiagen), from which complementary DNA
was reverse-transcribed using SuperScript II (Invitrogen) and random primers
(Invitrogen). Quantitative PCR was performed using SYBR Green (Applied
Biosystems) in ABI QuantStudio 7 (Applied Biosystems). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) housekeeping gene was used to normalize
samples. The list of primers used is shown in Supplementary Table 1.
Total RNA in BAT was isolated by using Trizol Reagent (Invitrogen) according
to the manufacturer’s protocol (RNA was precipitated with chloroform and
isopropanol, washed with 75% ethanol, and finally dissolved in RNAse-free water).
Complementary DNA synthesis was performed with MMLV enzyme (Invitrogen)
following supplier protocol. Real-time PCR (TaqMan; Applied Biosystems) was
performed using specific sets of primers, shown in Supplementary Table 1. All
reactions were carried out using the following cycling parameters: 50 C for 2min,
95 C for 10min followed by 40 cycles of 95 C for 15 s, 60 C for 1min32. For
PRDM16 assay, ID Mm01266512_m1 (Applied Biosystems TaqMan Gene
Expression) was used. Values were expressed relative to hypoxanthine–guanine
phosphoribosyltransferase levels.
Nuclear magnetic resonance analysis. For the measurement of body
composition, nuclear magnetic resonance imaging (Whole Body Composition
Analyzer; EchoMRI; Houston, TX) was used. EchoMRI is a body composition
analyser for live subjects that measures body fat and lean masses within short scan
times (to keep the measurement as comfortable as possible for the animals). Mice
were not under anaesthesia and no special preparation was needed before the
measurements. Mice were placed in a holder of custom-defined size during the
measurement (measuring time ranged between 0.5 and 3.2min)32–34.
Calorimetric measurements. Mice were analysed for locomotor activity, energy
expenditure and respiratory quotient using a calorimetric system (LabMaster; TSE
Systems; Bad Homburg). This system is an open-circuit instrument that determines
O2 consumption, CO2 production and respiratory quotient (vCO2/vO2)32–34. Mice
were acclimated for 1 week before starting the measurements.
Thoracic sympathetic ganglia analysis. Thoracic sympathetic ganglia (T1–12)
were dissected from TH-Cre; LSL-ChR2-YFP35 and T13 was dissected from
TH-Cre; LSL-GFPL10 (ref. 36) 6–8-week-old mice, fixed in 4% formaldehyde for
2 h and stained using anti-TH (1:1000, Pel-freez, #P40101-150) and anti-GFP
(1:1000, Abcam, #ab13970) antibodies. Z-series stacks were acquired on a Leica
TCS SP5 confocal Inverted microscope. Analysis and quantification of images were
performed in FIJI.
Western blotting. Dissected BAT was homogenized and lysed with buffer with the
following composition: Tris-HCl pH 7.5 50mM, EGTA 1mM, EDTA 1mM,
Triton X-100 1% v/v, sodium orthovanadate 0.1mM, sodium fluoride 50mM,
sodium pyrophosphate 5mM, sucrose 0.27M and protease inhibitor cocktail
(Roche Diagnostics)37. The protein concentration was determined by the Bradford
method. Protein lysates were subjected to SDS–polyacrylamide gel electrophoresis,
electrotransferred on a polyvinylidene difluoride membrane and probed with the
following antibodies: UCP1 (1:10,000, Abcam, #ab10983) and a-tubulin (1:5,000,
Sigma, T5168)32–34. Then, the membrane was incubated with the corresponding
secondary antibody: anti-mouse or anti-rabbit (all of them from DAKO, Denmark
A/S). The membranes were exposed to an X-ray film and developed using
Developer (Developer G150) and Fixator (Manual Fixing G354). The
quantification was done with the ImageJ program. Values were expressed in
relation to a-tubulin protein levels.
Protein quantification. BAT, SubQ and visceral dissections were weighed and
homogenized in lysis buffer (consisting of a mix of 5ml Tris-HCL, 0.5ml 0.2M
EGTA, 0.5ml 0.2M EDTA, 1ml Triton X-100, 1ml 0.1M sodium orthovanadate,
0.21 g sodium fluoride, 0.22 g sodium pyrophosphate and 9.2 g of 0.27M sucrose,
made up with distilled water to 100ml and adjusted to pH 7.5) and freshly added
protease inhibitor cocktail tablets (Roche Diagnostics). The protein concentration
was determined by the Bradford Method, and the total protein content of the
tissues was calculated32–34.
Statistical analysis. All the statistical analysis were performed in Sigma Plot 11.0,
using unpaired t-test when two groups were being compared or one-way ANOVA
test (followed by Tukey test) when several groups were being compared (more
specifically in Figs 1 and 2). A P-valueo0.05 was considered as statistically
significant. Data were represented as mean±s.e.m.
Data availability. The data that support the findings herein presented are available
from the corresponding author upon reasonable request.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14967 ARTICLE
NATURE COMMUNICATIONS | 8:14967 | DOI: 10.1038/ncomms14967 | www.nature.com/naturecommunications 9
References
1. Picklo, M. J. Methods of sympathetic degeneration and alteration. J. Auton.
Nerv. Syst. 62, 111–125 (1997).
2. Bezna´k, A. B. L. & Hasch, Z. The effect of sympathectomy on the fatty deposit
in connective tissue. Q. J. Exp. Physiol. 27, 5–12 (1937).
3. Cousin, B. et al. Local sympathetic denervation of white adipose tissue in rats
induces preadipocyte proliferation without noticeable changes in metabolism.
Endocrinology 133, 2255–2262 (1993).
4. Youngstrom, T. G. & Bartness, T. J. White adipose tissue sympathetic nervous
system denervation increases fat pad mass and fat cell number. Am. J. Physiol.
275, 1488–1493 (1998).
5. Zeng, W. et al. Sympathetic neuro-adipose connections mediate leptin-driven
lipolysis. Cell 163, 84–94 (2015).
6. Buch, T. et al. A cre-inducible diphtheria toxin receptor mediates cell lineage
ablation after toxin administration. Nat. Methods 2, 419–426 (2005).
7. Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev.
Drug Discov. 2, 214–221 (2003).
8. Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery.
Drug Discov. Today 10, 1451–1458 (2005).
9. Jevsˇevar, S., Kunstelj, M. & Porekar, V. G. PEGylation of therapeutic proteins.
Biotechnol. J. 5, 113–128 (2010).
10. Milla, P., Dosio, F. & Cattel, L. PEGylation of proteins and liposomes:
a powerful and flexible strategy to improve the drug delivery. Curr. Drug
Metab. 13, 105–119 (2012).
11. Savitt, J. M., Jang, S. S., Mu, W., Dwason, V. L. & Dawson, T. M. Bcl-x is
required for proper development of the mouse substantia nigra. J. Neurosci. 25,
6721–6728 (2005).
12. Youngstrom, T. G. & Bartness, T. J. Catecholaminergic innervation of white
adipose tissue in siberian hamsters. Am. J. Physiol. 268, R744–R751 (1995).
13. Winer, S. et al. Normalization of obesity-associated insulin resistance through
immunotherapy. Nat. Med. 15, 921–929 (2009).
14. Stachowiak, M. K., Fluharty, S. J., Stricker, E. M., Zigmond, M. J. & Kaplan, B. B.
Molecular adaptations in catecholamine biosynthesis induced by cold stress and
sympathectomy. J. Neurosci. Res. 16, 13–24 (1986).
15. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological
significance. Physiol. Rev. 84, 277–359 (2004).
16. Virtue, S. & Vidal-Puig, A. Assessement of brown adipose tissue function.
Front. Physiol. 4, 128 (2013).
17. Tsai, H. C. et al. Phasic firing in dopaminergic neurons is sufficient for
behavioral conditioning. Science 324, 1080–1084 (2009).
18. Domingos, A. I. et al. Leptin regulates the reward value of nutrient. Nat.
Neurosci. 14, 1562–2568 (2011).
19. Chaudhury, D. et al. Rapid regulation of depression-related behaviors by
control of midbrain dopamine neurons. Nature 493, 532–536 (2013).
20. Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for
modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001).
21. Veronese, F. M. Peptide and protein PEGylation: a review of problems and
solutions. Biomaterials 22, 405–417 (2001).
22. Oldendorf, W. H. The blood-brain barrier. Exp. Eye Res. 25, 177–190 (1977).
23. Witt, K. A., Gillespie, T. J., Huber, J. D., Egleton, R. D. & Davis, T. P. Peptide
drug modifications to enhance bioavailability and blood-brain barrier
permeability. Peptides 22, 2329–2343 (2001).
24. Levin, B. E., Triscari, J., Marquet, E. & Sullivan, A. C. Dietary obesity and
neonatal sympathectomy. I. Effects on body compostition and brown adipose.
Am. J. Physiol. 247, R979–R987 (1984).
25. Freeman, P. H., Wellman, P. J. & Clark, D. E. Effects of guanethidine
sympathectomy on feeding, drinking, weight gain and amphetamine anorexia
in the rat. Physiol. Behav. 35, 473–477 (1985).
26. Tordoff, M. G. Influence of sympathectomy on body weight of rats given chow
or supermarket diets. Physiol. Behav. 35, 455–463 (1985).
27. Desautels, M. & Dulos, R. A. Effects of neonatal sympathectomy on brown fat
development and susceptibility to high fat diet induced obesity in mice. Can. J.
Physiol. Pharmacol. 69, 1868–1874 (1991).
28. Bove´, J., Prou, D., Perier, C. & Przdborski, S. Toxin-induced models of
Parkinson’s disease. NeuroRx 2, 484–494 (2005).
29. Arvaniti, K., Deshaies, Y. & Richard, D. Effect of leptin on energy balance does
not require the presence of intact adrenals. Am. J. Physiol. 275, 105–111 (1998).
30. Reis, B. S. et al. Leptin receptor signaling in T cells is requires for Th17
differentiation. J. Immunol. 194, 5253–5260 (2015).
31. Gabanayi, I. et al. Neuro-immune interactions drive tissue programming in
intestinal macrophages. Cell 164, 378–391 (2016).
32. Martı´nez de Morentin, P. B. et al. Estradiol regulates brown adipose tissue
thermogenesis via hypothalamic AMPK. Cell Metab. 20, 41–53 (2014).
33. Martı´nez de Morentin, P. B. et al. Nicotine induces negative energy balance
through hypothalamic AMP-activated protein kinase. Diabetes 61, 807–817
(2012).
34. Martins, L. et al. A functional link between AMPK and orexin mediates the
effect of BMP8B on energy balance. Cell Rep. 23, 2231–2242 (2016).
35. Daou, I. et al. Remote optogenetic activation and sensitization of pain pathways
in freely moving mice. J. Neurosci. 33, 18631–18640 (1993).
36. Malin, S. A., Davis, B. M. & Molliver, D. C. Production of dissociated sensory
neuron cultures and considerations for their use in studying neuronal function
and plasticity. Nat. Protoc. 2, 152–160 (2007).
37. Lo´pez, M. et al. Hypothalamic AMPK and fatty acid metabolism mediate
thyroid regulation of energy balance. Nat. Med. 16, 1001–1008 (2010).
Acknowledgements
This work was supported by the Fundac¸a˜o para a Cieˆncia e Tecnologia
(PTDC/BIM-MET/3750/2014), the European Molecular Biology Organization (EMBO),
European Community’s Seventh Framework Programme (FP7/2007-2013) under
agreement no. 281854—the ObERStress project, MINECO co-funded by the FEDER
Program of EU (ML: SAF20015-71026-R) and Xunta de Galicia (ML: 2015-CP079). The
FCT, IGC and EMBO supported M.M.A.P., I.M., E.S., N.K., R.M.P. and A.I.D. G.J.L.B. is
a Royal Society University Research Fellow and a FCT Investigator. We thank Dr Len
Packman for the mass spectrometry services and Professor Carlos Roma˜o for useful
discussions. We thank Colin Adrain and Lars Jansen for critical reading of the
manuscript.
Author contributions
A.I.D. conceived the experimental strategy; G.J.L.B. conceived the protein modification;
P.C. provided intellectual input on thermogenesis; M.O.D. contributed to the
calorimetric studies. PEGylation was performed by M.M.A.P.; cell culture and FACS
were conducted by E.S. and M.M.A.P.; M.M.A.P. developed PEGyDT-mediated
sympathectomy; M.M.A.P., E.S., N.K. and R.M.P. performed functional tests; I.M.
conducted quantitative PCR and NE measurements; N.M. and M.L. performed nuclear
magnetic resonance, locomotor activity, energy expenditure and respiratory quotient
analysis; N.M. and M.L. performed PCR with reverse transcription and western blotting
in BAT as well as protein quantification; rodent husbandry was performed by N.K.;
A.I.D. and M.M.A.P. wrote the manuscript; all authors revised the manuscript. G.J.L.B.
and A.I.D. are co-senior authors of this work.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Pereira, M. M. A. et al. A brain-sparing diphtheria toxin for
chemical genetic ablation of peripheral cell lineages. Nat. Commun. 8, 14967
doi: 10.1038/ncomms14967 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14967
10 NATURE COMMUNICATIONS | 8:14967 | DOI: 10.1038/ncomms14967 | www.nature.com/naturecommunications
